Abstract: World Health Organization (WHO) declared tuberculosis (TB) as a global emergency in 1993, and recommends the approach developed by the Stop TB Partnership. Targets set by the Partnership are as follows: by 2015, reduce prevalence and death rates by 50%, compared with their levels in 1990, and by 2050, eliminate TB as a public health problem, defined as a global incidence of active TB of less than one case per 1 million population per year. The basic objective of this study is to test whether these targets will be realised on schedule. We have selected 22 so-called high-burden countries that account for over 80% of the world's TB cases. For each country, we have developed a forecasting model based on experience curve for incidence, prevalence, and mortality rate. After projecting the future rates for 2015 and 2050, we compare our projections with the future targets set by the Partnership.
Introduction
Tuberculosis (TB) which is a contagious and airborne disease ranks as the second leading cause of death among infectious disease worldwide after the HIV (WHO, 2013a (WHO, , 2013b . According to the World Health Organization (WHO), more than 8.7 million new cases of tuberculosis have occurred and 1.4 million people have died from TB in 2011. Though there have been significant progress made by the international community and international organisations to eliminate TB as a global epidemic, 9 million or more new cases still occur each year and the incidence rate is falling at less than 1% each year (Lönnroth et al., 2010a (Lönnroth et al., , 2010b .
Historically, the WHO declared TB as a global health emergency in 1993. Since then, three major strategies to control TB were introduced: directly observe therapy (DOTS, 1991 (DOTS, -2005 , Millennium Development Goals by the United Nations (MDGs, 2002 (MDGs, -2015 , and the Global Plan to Stop TB (2006 -2015 . The DOTS strategy, established by the WHO, included five key components of controlling TB, 1 which was widely accepted by many countries and showed significant success in terms of treatment of TB (Onozaki and Raviglione, 2010; Lienhardt et al., 2012; Glaziou and Raviglione, 2010; Dye et al., 2013; Hargreaves et al., 2011; Lönnroth et al., 2010a Lönnroth et al., , 2010b Marais et al., 2010; Mohapatra, 2009; Rasanathan et al., 2011; Small and Pai, 2010; Villemagne et al., 2012) . To accelerate the progress, with many health-related organisations' effort, the Stop TB Partnership was established as a global movement and it launched the Global Plan to Stop TB in 2006 . The Stop TB Partnership set the following targets for 2015 and 2050:
• by 2015, reduce prevalence and mortality rate by 50%, compared with their levels in 1990
• by 2050, eliminate TB as a global health problem, defined as a global incidence of active TB of less than one case per million population per year (Stop TB Partnership, 2011) .
These goals have been adopted as the MDG Goals 6C. 2 Here, the incidence, prevalence, and mortality rates of TB are defined as follows: incidence is the number of new and current episodes of TB occurring in a given year; prevalence is the number of TB cases at a given point in time; and mortality is the number of deaths caused by TB in HIVnegative people (WHO, 2013a (WHO, , 2013b .
There are a number of well-known studies to evaluate the progress of eliminating tuberculosis (WHO, 2013a (WHO, , 2013b Dye, 2006; Dye and Williams, 2007; Murray and Lopez, 1997; Maher et al., 2007; Mathers and Loncar, 2006; Lönnroth et al., 2010a Lönnroth et al., , 2010b . Our paper attempts to add long-term country-specific projection for 2015 and 2050 to evaluate whether the Partnership goals can be met on schedule. In our paper, instead of more traditional multivariate models, we propose a simple forecasting model using learning or experience curve, which has been widely used as a forecasting model in areas including health, industry, and energy sectors (Chang et al., 2012a (Chang et al., , 2012b Lee, 2012, 2013) .
The rest of this paper is organised as follows. In Section 2, we briefly review literatures on projection of TB rates and on the experience curve model. In Section 3, we will explain the methodology and data that are used for the analysis. In Section 4, we will present our own projections on the incidence, prevalence, and mortality rate of TB for 22 countries and compare our own projections with the Global Plan to Stop TB targets. At last, in Section 5, we will discuss our findings and provide conclusions and limitations of the research.
Literature review
There are many papers that deal with the progress and long-term projections of TB, and we present a partial list of the most prominent papers in Table 1 below. Among those studies dealing with the long-term projections, the papers by Murray and Lopez (1997) and Mathers and Loncar (2006) are generally viewed as the most authoritative. Table 1 List of major literatures on TB Author (year) Summary of literature Murray and Lopez (1997) As part of the Global Burden of Disease Study, authors created three scenarios (optimistic, baseline, pessimistic) of future mortality and disability for different age-sex groups, causes and regions. Authors concluded that TB, being one of the causes of global mortality, is projected to be still one of the top 10 leading causes of death in 2020 Mathers and Loncar (2006) Following the work by Murray and Lopez (1997) , Mathers and Loncar made new projections of mortality and burden of disease to 2030. Based on the similar analysis done in previous work, the study projects that TB will still be a part of top 10 leading causes of death in 2030 Stop TB Partnership (2011) The Partnership estimates that the TB incidence rate has been falling continuously, and MDG target -that TB incidence should be falling by 2015 -will be eventually achieved globally. Also, it is projected that the goal to halve TB prevalence and mortality rate by 2015 could be achieved in all regions except Africa and South-East Asia WHO (2013a WHO ( , 2013b Through the surveys and surveillance, the WHO estimated the incidence, prevalence, and mortality rates of TB up to year 2015. The study concludes that incidence and mortality rates has been falling constantly and will eventually achieve the target, but will be impossible to achieve the target for the prevalence rate
As a part of the Global Burden of Disease Study, Murray and Lopez developed series of future scenarios of health status based on the projected changes in key socio-economic variables, which they believe affect the health status. To simplify the analysis, they categorise diseases into three categories and developed three scenarios (optimistic, pessimistic, and baseline) to project mortality rate and burden of disease in 2020 and 2030. In the two studies, first conducted by Murray and Lopez (1997) and later by Mathers and Loncar (2006) , TB is treated as one of the leading causes of mortality and global burden of disease. They used projections to determine how much it will contribute to the global disease in 2020 and 2030. Both studies have concluded that TB, being the second leading cause of death currently, will fall to the 9th leading cause of death by 2040. On the other hand, both studies imply that a majority of countries will not be able to meet the 2015 and 2050 targets. However, we were unable to find the studies in the literatures where country-specific long-term projections of incidence, prevalence, or mortality rate of TB were available through 2050.
Methodology and data

Methodology
This study will use two types of experience curves, classical and kinked experience curve. In both experience curves, the independent variable is the cumulative population size and the dependent variable is incidence, prevalence, and mortality rates for individual countries. Our analysis begins from 1990 through 2010 for all sample countries due to the availability of data. The experience curve model is based on a simple concept of 'learning by doing' or 'practice make it perfect'. In other words, the more practices or experiences that nation has acquired in dealing with TB infection, the better outcome from TB infection can be expected. Better outcome means lower incidence, prevalence, and death rates in the future, which will be projected from our model. What measure can best represent the cumulative experience of dealing with TB infections? Because all three rates under analysis are calculated per 100,000 populations, the most logical candidate to measure the degree of experience in the past as well as the future is the cumulative population size of respective countries. However, cumulative population we use is not the absolute size.
To be more precise, the relationship between dependent variable and independent variable is logarithmic in experience curve model. So far, experience curve presented is assumed to have a constant improvement rate. However, the so-called kinked experience curve model which can accommodate multiple improvement rates will also be used in this study. Kinked model will have two separate equations, one for the early phase and another for the second phase where slopes during the second phase display greater improvement of performance measure. These experience curve models with multiple slopes are known as kinked models. For further explanation of kinked experience curve models and their applications, the reader is referred to a review (Chang and Lee, 2014) .
Therefore, a percentage change of cumulative population will determine a percentage reduction of the three TB rates. We will report on how well the relationship has held for these countries after our analysis is completed.
The classical experience curve equation can be expressed as:
where y: subject rate per population of 100,000 a:
cumulative population beginning 1990 b: classical experience slope For the kinked experience curve model, the following two equations are used:
For the year of 1990 through one year before the kinked year where b 1 = experience slope for equation (2) 
For the time period from the kinked year through 2010 where b 2 = experience slope for equation (3). In logarithmic form, the classical experience equation would be:
In logarithmic form, the kinked experience equation for the first period would be:
And the kinked experience equation for the second period would be:
We can combine the two kinked experience equations in logarithmic form (2a) and (3a), using a dummy variable which takes the value of one if the year belongs to the second period and zero otherwise:
where, P = 0, if t = 1990, 1991, 1992, …, k -1, P = 1, if t = k, k + 1, …, 2010. To find a kinked year for each country, we test all possible years, from 1990 through 2010, looking for the highest value of R 2 , coefficient of determination, using equation (4). The year that shows the highest R 2 is selected as the kinked year for the country. Then, we test whether the difference between the slopes of a kinked experience curve from the first period and the second period, represented by b 1 and b 2 , is statistically significant. If the difference is statistically significant, we choose the kinked experience curve equation (3). Otherwise, we select the classical experience equation (1).
For the projection of the future TB rates with the experience model, we need to use the future annual population. In order to estimate the cumulative population up to 2015 and 2050 for each country, we use the past annual population figure as well as future population projections available from the US Census International Database. We, then, add these projected figures to the actual cumulative population figure from 1990 to 2010. Finally, we use either estimated classical or estimated kinked experience curve equations for individual countries to forecast the future rates for 2015 and 2050. To calculate the standard error and its confidence interval of our projections, we follow the procedures suggested by Wooldridge (2008) .
Data
For this paper, we collected the incidence, prevalence, and mortality rate of TB for 22 countries with high burden of TB that together have more than 80% of world's cases. The 22 countries are Afghanistan, Bangladesh, Brazil, Burma, Cambodia, China, DR Congo, Ethiopia, India, Indonesia, Kenya, Mozambique, Nigeria, Pakistan, Philippines, Russia, South Africa, Thailand, Uganda, Tanzania, Vietnam, and Zimbabwe (WHO, 2013a (WHO, , 2013b . Each country's TB rates from 1990 to 2010 were collected from the UN's Millennium Development Goals Indicators (United Nations, 2011). Also, both the past and the future annual population figures are obtained from the US Census International Database (US Census Bureau, 2011).
In case of incidence rate, only 16 out of the 22 countries had a complete set of data so that 6 countries were excluded from our analysis.
Results
Historical analysis on incidence, prevalence, and mortality rates of TB
At first, in order to examine whether each country's past data fits better into the classical or kinked experience model, we ran the analysis of both models on incidence, prevalence, and mortality rates. The results are as follows: 3 countries (Ethiopia, Kenya, and Mozambique) for the incidence rate, 2 countries (Ethiopia and Russia) for the prevalence rate, and 6 countries (Ethiopia, Kenya, Russia, South Africa, Tanzania, and Vietnam) for the mortality rate have the values of b 2 -b 1 which are statistically insignificant. Thus, we conclude that these countries fit better to the classical experience curve model. For each of the rest of the countries, the difference between the slopes of the two equations in the kinked model, b 2 -b 1, is statistically significant; therefore, we select kinked experience curve model for the projection purpose.
To elaborate, Figure 1 and Table 2 show the historical experience curve of the incidence rate for Cambodia as an example of kinked experience curve model. As one can note from Figure 1 , the kinked experience slope of 91% is lower by 3% than the classical experience curve. Also in Table 2 , the value of b 2 -b 1 is statistically significant at p-value of 0.01: thus, we select kinked model over classical model. Following the same procedures we show the results of our regression analysis of both classical and kinked experience equations for incidence, prevalence, and mortality rates in Appendix  Tables A1-A3 . From these analyses, we have discovered that a majority kinked years occurred between 1996 and 2002, whereas the experience slope ranged between 50% and 90%. For example, the experience slope of 50% means that doubling the cumulative experience will generate performance improvement of 29.3% (1 -2 -5 = 0.293). The selected experience slopes and kinked years for incidence, prevalence, and mortality rates are shown in Figures 2-4 . From these analyses, we can conclude that majority of countries are represented by kinked model and majority of countries have R 2 of 0.9 or higher. Also, a majority of countries (12 countries for incidence rate, 18 countries for prevalence rate, and a majority of countries have their kinked years occurring between 1996 and 2003 (14 countries for incidence rate, 20 countries for prevalence rate, and 17 countries for mortality rate).
Projection of incidence, prevalence, and mortality rates for 2015 and 2050
Next, we proceed to use the kinked or the classical equation selected for each country to project appropriate future rates for years 2015 and 2050. To project these future rates, we first calculate the cumulative population size from 1990 through years 2015 and 2050. Then, we forecast TB rates by using the kinked and the classical experience curve equation selected earlier. The projected future rates are then multiplied by the projected annual population size for the years 2015 and 2050 in order to obtain projected TB rates for these years. Since the prevalence rate of Cambodia in 1990 is 1258 per 100,000 populations, the percentage reduction of Cambodia by 2015 and 2050 are calculated as 53.8% and 72.7%. The details of our projection for selected years through 2050 are presented in Table 3 . Therefore, we conclude that the percentage reduction of Cambodia will exceed the Partnership target of 50% reduction by 2015.
For all other countries, the same projection steps were applied to obtain future rates of TB, and results are presented in Appendix Tables A4-A6 . Also, Figures 5-7 shows the percentage reduction of incidence, prevalence, and mortality rates in comparison to 1990 rates. Furthermore, we estimate the confidence intervals of our projections to determine the statistical validity of our 2015 projections of prevalence and mortality rates in comparison with the Partnership's targets in Appendix Table A7 .
The result of our analysis as shown in Figure 5 indicates that 9 out of 22 countries (Uganda, China, Brazil, Philippines, India, Cambodia, Burma, Nigeria, and Vietnam) will exceed the 50% reduction target of prevalence rate by 2015. Fortunately, large populated countries like China (68%), Brazil (62%), and India (55%) are among those exceeding the 50% target. When 99% confidence intervals are used for projection as shown in Table 7 , two more countries (Pakistan and Tanzania) will also exceed the 2015 target. However, there are four countries (Kenya, Zimbabwe, South Africa, Ethiopia) identified as outliers due to their increasing, not decreasing prevalence rate. Furthermore, five more countries (Afghanistan, Indonesia, Mozambique, Pakistan, and Tanzania) will exceed the 50% reduction target of prevalence rate by 2050, making a total of 14 countries. The remaining four countries (Russia, Bangladesh, DR Congo, and Thailand) will have their prevalence rates continue declining. Nevertheless, they will not meet the 2015 target even by 2050.
As for mortality rate, 9 out of 22 countries (Uganda, China, Burma, Brazil, Philippines, India, Cambodia, Indonesia, and Nigeria) will meet the 50% reduction target by 2015. When 99% confidence intervals are used for projection as shown in Table 7 , three more countries (Afghanistan, India, and Mozambique) will also exceed the target by 2015. However, the same four countries identified as outliers are again showing increasing mortality rates in the future.
Out of the remaining 9 countries, all of them with the exception of Vietnam will also meet the 50% reduction target by 2050. As for incidence rate reduction target, 11 out of 16 countries analysed will have their incidence rates declining through 2015 compared to their 1990 rates. However, none of 16 countries analysed will meet the 2050 reduction target on time as shown in Figure 7 . Furthermore, there are five outliers including the same four countries identified earlier who display increasing incidence rates in the future. Table A8 shows that even the best incidence rate projected for Brazil among 16 countries of 26.97 per 100,000 populations is significantly above the 2050 target of 0.1 per 100,000 populations.
Conclusion
Our projected numbers of countries meeting the 50% reduction target of the Stop TB Partnership in prevalence and mortality rates are remarkably close to the numbers projected by the latest WHO's Global Tuberculosis Report of 2013 (GTR2013). In both prevalence and mortality rates, GTR 2013 projects 11 out of 22 high burden countries meeting the 50% reduction targets by 2015. In comparison, we project 9 out of 22 countries meeting the 2015 target in both prevalence and mortality rate out of 22 countries. When our projections are made with 99% confidence interval, our projected number of countries in prevalence rate is increased to the same number of 11 countries. In case of mortality rate, our projected number of countries increases to 12 countries, one more than the number by GTR 2013.
GTR 2013 states that "among the 22 HBCs, 11 are not on track to reduce incidence, prevalence, and mortality in line with targets. Reasons include resource constraints, conflict and instability, and generalised HIV epidemics" 3 However, our analysis goes beyond the year of 2015 for each of these 11 countries. We project that 5 more countries for prevalence rate and 8 more countries for mortality rate will eventually meet the 50% reduction target before 2050. Nevertheless, four to five outliers we identified earlier are projected to continue their increasing rates throughout the future years. The last remaining group of countries, Bangladesh, DR Congo, Russia, and Thailand in case of prevalence rate and Vietnam in case of mortality rate will require more time even beyond 2050 to meet the 50% reduction target. In case of incidence rate reduction target of 2050, none of the countries will be able to achieve the target by 2050 or beyond.
The most obvious policy implication, therefore, is to re-evaluate the 2050 incidence rate target to make it more realistic and useful. As for those countries not able to meet the 2015 reduction target even by 2050, they obviously require special types of assistance from both within and outside of the countries. The same type of help may be needed for some of those countries not being able to meet the reduction target for many years beyond 2015.
As far as we are aware, this may be the first application of the experience curve equations to project long-term TB rates through 2050. Our results indicate that the usefulness of experience curve equations, in particular kinked equation, has been demonstrated. High values of R 2 obtained from respective experience equations also suggest that the use of cumulative population as independent variable appears reasonable. The use of simple experience curve equation, together with effective use of vest pool of data available on the web, enables us to make this long-term projection possible. We believe that the methodology we employed here may be used for future extension of the TB Partnership targets as well as some other Millennium Development Goals to obtain quick and rough initial estimates.
Improvement to the methodology we used can be made in the future. Future TB rates generally reflect interplay of many complex factors. These factors may include population dynamics, health status of individuals, income level, and environmental elements affecting health as well as health infrastructure in different countries. Furthermore, future TB rates will be influenced by development of new and better diagnostic and other technologies and medicines, availability of global assistance and funding, the effectiveness of local administration and many others (Lönnroth et al., 2010a (Lönnroth et al., , 2010b Dye et al., 2009; Dye and Williams, 2010; Pai et al., 2010; Gandhi et al., 2010) .
The question is how can experience curve equation using the cumulative population size as a sole independent variable represent these multiple factors. Obviously, not all of these factors can be included in the experience curve model explicitly. However, the experience curve equation, in general, implicitly incorporates multiple factors which influence developing trend of TB rates. For example, improvement effects from experience, in general, include learning from doing, learning from researching, learning from using, and learning from others as well as learning from scaling and from new technology (Weiss et al., 2010; Ferioli et al., 2009; Kahouli-Brahmi, 2008) .
On the other hand, whenever there are important explicit factors which can be measured, experience curve model should be expanded to incorporate such factors. Alternatively, the use of experience curve model representing top-down approach of analysis may be combined with detailed button-up analysis for a set of factors unique to individual countries (Neij, 2008) .
Notes
1 The five components of DOTS strategy are as follows: political commitment; case detection among symptomatic patients presenting spontaneously in health services; standardised short-course chemotherapy to all confirmed sputum smear-positive cases, provided under proper case management conditions; an effective drug supply system; and a standardised system for surveillance and program monitoring. 2 The United Nation's Millennium Development Goal 6C indicates the following goal: Have halted by 2015 and begun to reverse the incidence of malaria and other major diseases. Specifically, for TB, the goal is that the anti-tuberculosis drive is closing on a 50% cut in the 1990 death rate and more TB patients are being successfully treated. 3 GTB-2013, p.ix. 
